What is PathAI?
Headquartered in Boston, Massachusetts, PathAI collaborates with leading life sciences companies and researchers to drive advancements in precision medicine. The company's sophisticated AI platform is designed to enhance diagnostic accuracy and improve the effectiveness of treatments for diseases such as cancer. PathAI's technology is crucial for pathologists and researchers seeking to leverage artificial intelligence for more precise and efficient disease analysis, thereby accelerating the development of targeted therapies and improving patient outcomes.
How much funding has PathAI raised?
PathAI has raised a total of $180.2M across 3 funding rounds:
Other Financing Round
$4.2M
Series A
$11M
Series C
$165M
Other Financing Round (2016): $4.2M with participation from Pillar VC, 8VC, Fairhaven Capital, and Refactor Capital
Series A (2017): $11M led by General Catalyst, Pillar VC, KdT Ventures, Danhua Capital, 8VC, and Refactor Capital
Series C (2021): $165M supported by Biospring Partners, 8VC, Adage Technologies, Kaiser Permanente, Tiger Global Management, General Atlantic, Polaris Partners, Bristol-Myers Squibb, Refactor Capital, General Catalyst, Merck Global Health Innovation Fund, KdT Ventures, D1 Capital Partners, and Labcorp
Key Investors in PathAI
Biospring Partners
Biospring Partners is a venture capital firm specializing in technology-enabled businesses within the pharma services sector, focusing on innovation in manufacturing and clinical trial services to enhance the life sciences industry.
8VC
8VC is a technology investment firm backing visionary teams and industry-transforming companies, with a focus on smart enterprise platforms across various sectors including healthcare and Bio-IT.
Adage Technologies
Adage Technologies is a web strategy, design, and development firm that delivers complex commerce solutions, partnering with clients to solve business problems and meet meaningful goals.
What's next for PathAI?
The substantial enterprise-level funding and recent strategic investment indicate PathAI is poised for significant scaling and further innovation. This capital infusion will likely fuel the expansion of its AI platform, enhance its research and development capabilities, and broaden its market reach within the life sciences and healthcare sectors. PathAI's continued focus on improving diagnostic accuracy and treatment efficacy suggests a strategic trajectory aimed at becoming an indispensable partner in the global effort to advance precision medicine and combat complex diseases.
See full PathAI company page
